Skip to content

The effect of a single dose of oral Pregabalin single oral dose of gabapentin on pain control

Comparison of the effect of a single dose of oral Pregabalin with single oral dose of gabapentin on acute pain management after tibia fixation surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201502126186N8
Enrollment
60
Registered
2015-03-10
Start date
2015-03-25
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain. Other specified disorders of bone

Interventions

Intervention 1: First group: patients receive 150 mg, oral pregabalin 1 hour before operation. Post operation, VAS, nausea, vomiting and vertigo before exit from recovery room, 6 and 12 hours after su
Treatment - Drugs
First group: patients receive 150 mg, oral pregabalin 1 hour before operation. Post operation, VAS, nausea, vomiting and vertigo before exit from recovery room, 6 and 12 hours after surgery were monit
In the Second group: patients receive 300 mg oral Gabapentin, 2 hours before operation. Post operation, VAS, nausea, vomiting and vertigo before exit from recovery room, 6 and 12 hours after surgery w

Sponsors

Vice chancellor for research of Guilan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between17 to 65 years old; ASA I, II; being candidate for tibial fixation orthopedic surgery and spinal anesthesia. Exclusion criterion: patient dissatisfaction for spinal anesthesia.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Before spinal anesthesia, before exit from recovery room, 6 and 12 hours after surgery. Method of measurement: Visual Analog Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahram Naderi Nabi

Guilan University of Medical Sciences

naderi_bahram@yahoo.com+98 13 3366 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026